New Three-Drug cocktail targets Hard-to-Treat myeloma

NCT ID NCT05060627

Ongoing Disease control Sponsor: PETHEMA Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of three drugs—belantamab mafodotin, carfilzomib, and dexamethasone—in people whose multiple myeloma has returned and is no longer responding to lenalidomide. The trial has two parts: first, finding the safest dose, then testing that dose in up to 60 patients. The goal is to see if the combination can shrink tumors and keep the cancer under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (a targeted antibody-drug) combined with carfilzomib and dexamethasone
What this could lead to: If successful, this could offer a new treatment option for patients with multiple myeloma that has returned after prior therapy.
What could go wrong: This is an early-phase trial with only 60 patients, so results may not apply broadly. The combination may cause side effects, including eye problems, and may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED MULTIPLE MYELOMA

Contacts and locations

Locations

Clínica Universidad de Navarra (CUN)

Pamplona, Spain
Complejo Hospitalario Santiago (CHUS)

Santiago de Compostela, Spain
Complejo Hospitalario Virgen del Rocío

Seville, Spain
H. Gregorio Marañón

Madrid, Spain
H. Morales Meseguer

Murcia, Spain
H. Son Llatzer

Palma de Mallorca, Spain
H. Universitario Marqués de Valdecilla

Santander, Spain
H. Universitario de Canarias

Santa Cruz de Tenerife, Spain
H.U. La Fe

Valencia, Spain
HUCA

Oviedo, Spain
Hospital Clinic

Barcelona, Spain
Hospital Germans Trias i Pujol (ICO BADALONA)

Badalona, Spain
Hospital Universitario 12 de Octubre

Madrid, Spain
Hospital Universitario de Salamanca

Salamanca, Spain
ICO Duran i Reynals

L'Hospitalet de Llobregat, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.